DKK4

DKK4 is a secreted Wnt antagonist that inhibits canonical Wnt/β-catenin signaling through high-affinity binding of its CRD2 domain to LRP6 and Kremen1, promoting proteasomal degradation of β-catenin and suppressing downstream targets including cyclin D1 and FZD6 (PMID:29925589, PMID:22249261, PMID:36181792). DKK4 is transcriptionally induced by Eda/Edar signaling in ectodermal placodes and repressed by DLX3-mediated H3K27me3 deposition at its promoter, while its mRNA is post-transcriptionally stabilized by LARP1-dependent deadenylation protection and METTL14-mediated m6A methylation (PMID:18508042, PMID:31202458, PMID:37070251, PMID:41208390). DKK4 activity is terminated by proteolytic cleavage during meibomian gland development, and its biological output is context-dependent: in colorectal cancer, tumor-secreted DKK4 inactivates β-catenin in stromal fibroblasts, reprogramming them into myofibroblasts that restrict primary tumor growth but enhance metastasis (PMID:27864382, PMID:38519641). Elevated DKK4 confers chemoresistance to fluorouracil in colorectal cancer and to docetaxel in non-small cell lung cancer (PMID:22216841, PMID:28981599).

1. 2008 High

   Identification of DKK4 as a direct Eda/Edar transcriptional target established how Wnt antagonism is embedded within ectodermal placode signaling, resolving the paradox that a Wnt-dependent pathway simultaneously induces its own inhibitor.

   Evidence Microarray profiling of eda−/− embryonic skin explants treated with recombinant Eda-A1 plus in situ hybridization

   PMID:18508042

   Open questions at the time

   • Direct promoter binding by Eda-activated transcription factors not shown for DKK4
   • Whether NF-κB directly drives DKK4 transcription or acts through intermediaries is unresolved
2. 2010 High

   Demonstrating that DKK4 overexpression selectively blocks secondary but not primary hair follicle induction revealed a Wnt-dependent, Eda-independent pathway for hair subtype specification mediated by DKK4.

   Evidence Transgenic Dkk4 overexpression in wild-type and Tabby (Eda−/y) mouse backgrounds with histological analysis

   PMID:20386733

   Open questions at the time

   • Endogenous Dkk4 loss-of-function phenotype in hair follicle patterning not tested
   • Downstream effectors beyond Shh not characterized
3. 2012 High

   Multiple studies converged to define DKK4 as a functional Wnt/β-catenin pathway inhibitor: DKK4 promotes proteasomal β-catenin degradation in hepatocellular carcinoma, confers fluorouracil chemoresistance through TFAP2E-dependent epigenetic regulation in colorectal cancer, and is secreted via exosomes upon APC restoration.

   Evidence Luciferase reporters, xenograft models, proteasome inhibitor rescue (HCC); TFAP2E methylation analysis and cell viability assays (CRC); exosome proteomics and methylation-specific PCR (APC/SW480)

   PMID:22216841 PMID:22249261 PMID:22740476

   Open questions at the time

   • Identity of the protease(s) responsible for β-catenin degradation downstream of DKK4 not defined
   • Exosomal DKK4 secretion mechanism not independently replicated
   • Whether TFAP2E directly represses DKK4 transcription or acts indirectly was not resolved at this stage
4. 2016 High

   Discovery that DKK4 is inactivated by proteolytic cleavage during meibomian gland development introduced post-translational regulation as a mechanism controlling DKK4 activity in vivo, explaining how Wnt signaling is progressively de-repressed.

   Evidence Transgenic mouse overexpression, organotypic culture, biochemical detection of cleaved vs. intact DKK4, Lrp6 overexpression rescue

   PMID:27864382

   Open questions at the time

   • Protease responsible for DKK4 cleavage not identified
   • Whether proteolytic inactivation operates in non-ectodermal tissues is unknown
5. 2018 High

   Atomic-resolution NMR structure of DKK4 revealed the two-CRD architecture, assigned LRP6 and Kremen1 binding to CRD2, and identified the NXI(R/K) motif in the N-terminal region as a secondary LRP6-binding element, providing the structural basis for synergistic Wnt inhibition.

   Evidence NMR structure determination, biophysical binding assays, mutagenesis, functional Wnt signaling assays

   PMID:29925589

   Open questions at the time

   • No co-crystal structure of DKK4 in complex with LRP6 or Kremen
   • Structural basis for selective inhibition of specific Wnt ligands not resolved
6. 2019 Medium

   Demonstrating that DLX3 suppresses DKK4 via H3K27me3 deposition at the DKK4 promoter linked chromatin-level regulation to DKK4 expression control in osteogenic differentiation.

   Evidence ChIP-qPCR for H3K27me3 at DKK4 promoter, lentiviral overexpression/knockdown of DLX3, osteogenic differentiation assays in bone marrow mesenchymal stem cells

   PMID:31202458

   Open questions at the time

   • Whether DLX3 directly recruits a H3K27 methyltransferase (e.g. EZH2) to DKK4 is not shown
   • Single lab finding without independent replication
7. 2022 Medium

   Identification of a Wnt3a/DKK4/AKT/s552-β-catenin negative feedback axis revealed that DKK4 inhibits colorectal cancer metastasis by suppressing FZD6 and AKT2-mediated β-catenin phosphorylation, extending the mechanism beyond canonical LRP6 antagonism.

   Evidence RNA-seq after DKK4 knockdown, luciferase reporters, Transwell assays, subcutaneous and metastatic mouse models

   PMID:36181792

   Open questions at the time

   • Whether DKK4 directly interacts with FZD6 or acts indirectly through LRP6 is unclear
   • AKT2/β-catenin mechanism not validated with kinase-dead mutants
8. 2023 Medium

   Revealing that LARP1 stabilizes DKK4 mRNA by blocking BTG2-dependent deadenylation established a post-transcriptional control layer for DKK4 expression in hepatoblastoma, linking O-GlcNAcylation of LARP1 to DKK4 protein output.

   Evidence RNA immunoprecipitation, RNA pulldown, poly(A)-tail length assays, mRNA stability assays in hepatoblastoma cell lines

   PMID:37070251

   Open questions at the time

   • Direct binding site of LARP1 on DKK4 mRNA not mapped
   • Whether LARP1-DKK4 mRNA stabilization occurs in non-hepatoblastoma contexts is unknown
9. 2024 Medium

   Demonstration that tumor-secreted DKK4 reprograms stromal fibroblasts into pro-metastatic myofibroblasts by paracrine β-catenin inactivation resolved the apparent paradox of a tumor suppressor gene promoting metastasis through non-cell-autonomous effects.

   Evidence CRC-fibroblast co-culture, mouse xenograft models, β-catenin chemical inhibitor (MSAB) phenocopy experiments

   PMID:38519641

   Open questions at the time

   • Fibroblast subtypes most responsive to DKK4 not defined
   • Whether DKK4-driven fibroblast reprogramming operates at the metastatic niche or only in primary tumors is not established
10. 2025 Medium

    Identification of METTL14-mediated m6A methylation of DKK4 mRNA as a driver of docetaxel resistance and M2 macrophage polarization added epitranscriptomic regulation as a further post-transcriptional control of DKK4 levels.

    Evidence MeRIP assay demonstrating m6A on DKK4 mRNA, METTL14 knockdown/rescue, mouse xenograft model in lung cancer

    PMID:41208390

    Open questions at the time

    • Specific m6A reader protein mediating DKK4 mRNA stabilization/translation not identified
    • Whether m6A regulation of DKK4 operates outside chemoresistant lung cancer is unknown

• Key unresolved questions include the identity of the protease(s) that cleave and inactivate DKK4, the structural basis of DKK4's selective inhibition of specific Wnt ligands, and whether the paracrine fibroblast-reprogramming mechanism operates across cancer types or at metastatic sites.
• Protease identity for DKK4 cleavage unknown
• No co-crystal structure of DKK4-LRP6 or DKK4-Kremen complex
• In vivo loss-of-function models (full knockout) in cancer context not reported